The International Linked Clinical Trials Committee
The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.
Patrik Brundin, M.D., Ph.D. (Scientific Committee chair)
Professor Roger Barker
Flint Beal, M.D.
Dr Camille Carroll
Mark R. Cookson, Ph.D.
Ted Dawson, M.D., Ph.D.
David Devos, Ph.D.
Tim Greenamyre, M.D., Ph.D.
Howard Federoff, M.D., Ph.D.
Brian Fiske, Ph.D.
Tom Folytnie, Ph.D.
Karl Kieburtz, M.D., MPH
Dimitri Krainc, M.D.
Andrew Lees, F.R.C.P., FMedSci
Mark Mattson, Ph.D.
Michael Schwarzschild, M.D., Ph.D.
David Simon, M.D.
David Sulzer, M.D.
Caroline Tanner, M.D., Ph.D., F.A.A.N.
John Trojanowski, M.D.
Director of Research and Development
Dr Richard Wyse
Deputy Director of Research
Dr Simon Stott
